Amarin Corporation plc (NASDAQ:AMRN) Q2 2019 Earnings Conference Call - Final Transcript
Jul 31, 2019 • 07:30 am ET
Welcome to Amarin Corporation's Conference Call to discuss its financial and operating results for the second quarter of 2019. This conference call is being recorded today, July 31, 2019. I would like to turn the conference over to Elisabeth Schwartz, Senior Director of Investor Relations of Amarin. Please go ahead.
Good morning. Please be aware that this conference call will contain forward looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include but are not limited to our current expectations regarding our commercial and financial performance, including levels of Vascepa shipments and prescriptions, Vascepa product and licensing revenues, costs and other commercial metrics, gross margin, expenditures and the adequacy of our financial resources, our current expectations for scientific presentations, publications, regulatory reviews and related timing thereof, our expectations that REDUCE-IT results could lead to a new treatment paradigm in the patient population studied, our plans and preparation for expanded promotion of Vascepa and related market positioning and potential, our plans to purchase additional supply of Vascepa and our goals regarding the timing and scope of international expansion and our current plans for sales force and other commercial expansion.
These statements are based on information available to us today, July 31, 2019. We may not actually achieve our goals, carry out our plans or intentions, or meet the expectations disclosed in our forward-looking statements. forward-looking statements. Actual results or events could differ materially, so you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into such as mergers, acquisitions, dispositions, joint ventures or any material agreements that we may enter into, amend or terminate.
For additional information concerning the factors that could cause actual results to differ materially, please see the Forward-looking Statements section in today's press release and the Risk Factors section of our quarterly report on Form 10-Q for the quarter ended June 30, 2019. These documents have been filed with the SEC and are available through the Investor Relations section of our website at amarincorp.com. We encourage everyone to read these documents.
This call is intended for investors in Amarin and is not intended to promote the use of Vascepa outside its approved indication. Please note that that we are also providing slides to accompany this morning's call. These slides, which can be found on our website at amarincorp.com, in the Investor Relations section, under the sub category Events and Presentations, summarize some of the key updates discussed on today's call. Finally, an archive of this call will be posted on the Amarin website, also in the Investor Relations section.
I'll now turn the call over to John Thero, President and Chief Executive Officer of Amarin. John?
Good morning. Thank you for joining us at this remarkable stage in Amarin's journey to introduce a new cost effective treatment paradigm